Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B Open-Label Study of Nimenrix in Healthy Infants in Finland
2020-005059-19Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease, sponsored by Pfizer. Primary endpoint: Safety of Nimenrix at 3 months. Started Jan 2021; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2020-005059-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005059-19.